Search research articles
Contact Us
Filters
Showing results (581-590 of 591) with videos related to
Page
of 60
Sort By:
European Urology
|
March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Nature Communications
|
December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer
Soumyajit Roy, Yilun Sun, Maha Hussain, et al.
The Prostate
|
May 6, 2025
Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant
A Mandl, M L Zahurak, N A Metri, et al.
Urologic Oncology
|
December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergency
John L Gore, Kristin Follmer, Jason Reynolds, et al.
The Journal of Urology
|
May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Vikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, et al.
The Lancet. Oncology
|
November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2016
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, et al.
European Urology
|
December 22, 2021
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
Anirban P Mitra, Vikram M Narayan, Sharada Mokkapati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2025
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
John L Gore, Erika M Wolff, Michael G Nash, et al.
Page
of 60
Search research articles
Search
Showing results (581-590 of 591) with videos related to
Sort By:
Page
of 60
European Urology
|
March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Nature Communications
|
December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer
Soumyajit Roy, Yilun Sun, Maha Hussain, et al.
The Prostate
|
May 6, 2025
Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant
A Mandl, M L Zahurak, N A Metri, et al.
Urologic Oncology
|
December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergency
John L Gore, Kristin Follmer, Jason Reynolds, et al.
The Journal of Urology
|
May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Vikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, et al.
The Lancet. Oncology
|
November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2016
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, et al.
European Urology
|
December 22, 2021
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
Anirban P Mitra, Vikram M Narayan, Sharada Mokkapati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2025
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
John L Gore, Erika M Wolff, Michael G Nash, et al.
Page
of 60